Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
399 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer Center |
| 3 |
| Dec 20, 2019 |
| clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00106301 | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | completed | Phase 2 | 2 | CelgeneINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT02700568 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors(FavorAx) | completed | Phase 2 | 21 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03379012 | Testosterone in Metastatic Renal Cell Carcinoma Patients(FARETES) | completed | Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00106613 | A Research Study for Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | terminated | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2019 | clinicaltrials |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | terminated | Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02843607 | Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01282463 | Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | completed | Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2019 | clinicaltrials |
| NCT03592199 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib(SuAx) | unknown | Phase 2 | 7 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04049344 | Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00005851 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 110 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | terminated | Phase 2 | 5 | Region SkaneOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT00569946 | Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) | completed | Phase 2 | 64 | PfizerINDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT01731158 | Sequential Therapy in Metastatic Renal Cell Carinoma(BERAT) | completed | Phase 2 | 22 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 18 | PfizerINDUSTRY | 2 | Jan 8, 2019 | clinicaltrials |
| NCT01743469 | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers | completed | Phase 2 | 201 | IpsenINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT01688973 | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01762150 | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | completed | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 361 | National Cancer Institute (NCI)NIH | 2 | Nov 14, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01158222 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | completed | Phase 2 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01158521 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | terminated | Phase 2 | 2 | Argos TherapeuticsINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population | terminated | Phase 2 | 13 | vghtpe userOTHER_GOV | 1 | Jun 26, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT00729053 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | completed | Phase 2 | 92 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01829841 | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer | completed | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 3, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 23, 2019source: clinicaltrials